NTRK1 and cancer: Trastuzumab is a recombinant humanized monoclonal antibody that inhibits tyrosine kinase receptor expressed on cancer cells; the same enzyme is also expressed on cardiomyocytes and its inhibition seldom provokes DCM, in a mostly reversible and dose-independent fashion (Type II cardiotoxicity) [64].